Two key appointments for Glox Therapeutics
14 Feb 2025
Glox Therapeutics, which specialises in development of precision antibiotic therapies based on naturally occurring bacteriocins, has announced two key appointments.
Dr Michael Murray becomes chair of the company board while Dr Nel Moore joins Glox’s scientific advisory board.
New chair Murray is the principal at Murray International Partners, with almost nearly 30 years’ experience in management roles at companies, including Metallobio, Porton Biopharma, EnteroBiotix, Sosei Heptares, and Amura Therapeutics, as well as an international commercial consultancy practice.
He also teaches commercial IP strategy on the Novo Nordisk Fellowship MBA in biomedical design programme in Denmark and has delivered training to over 1,200 individuals in the commercialisation of technical innovations since 2015.
Moore’s 21 year career includes work on global drug discovery, development and commercialisation in the areas of immunology, oncology and anti-infectives. She was formerly vice president of antibiotics development at AstraZeneca.
